H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $100.00 price target on BridgeBio Pharma (NASDAQ: BBIO).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments